Target intelligence / Profile preview

Mesenchymal stromal cell (MSC) (MSC)

Target
MSC
Molecular classification
Other
01

Overview

Mesenchymal stromal cells (MSCs) are multipotent adult stem cells found in various tissues, capable of differentiating into bone, cartilage, adipose, muscle, and other cell types. They contribute to tissue repair by responding to injury signals, secreting extracellular matrix components, cytokines, growth factors, and extracellular vesicles, and modulating the local and systemic environment to support regeneration. MSCs replenish stem cell pools, restore niches, and influence the behavior of differentiated cells via direct cell-cell interaction and paracrine signaling. Their therapeutic promise lies in their plasticity and immune modulatory properties, but efficacy may be limited by poor engraftment, unpredictable differentiation, and safety risks. Molecular mechanisms involve key pathways such as Hedgehog, Wnt, TGFβ, BMP, and FGF, which are targets for experimental drugs designed to enhance MSC function or direct their differentiation[1][2][4].

Other names
mesenchymal stem cellmesenchymal progenitor cellMSCmultipotent mesenchymal cell
02

Mechanism of action

Modulation of cell fate decisions via paracrine secretion of growth factors and cytokines[1]; Promotion of stem cell survival, differentiation, and proliferation through activation/inhibition of key signaling pathways (Hedgehog, Wnt, BMP, TGFβ, FGF, EGF)[2][4]; Direct differentiation into target tissue cell types (osteoblasts, chondrocytes, adipocytes, myocytes, hepatocytes, neuronal cells)[1][2][3][4]; Restoration of stem cell niches after injury by replenishing or attracting niche components[1]

03

Biological functions

Cell differentiationTissue repairStem cell homeostasisImmune regulationParacrine signalingExtracellular matrix productionCell proliferationApoptosisCell migration
04

Disease associations

CancerInflammationNeurodegenerative diseaseCardiovascular diseaseTissue degeneration/repairInfection
05

Safety considerations

Poor engraftment and limited efficacy in some clinical trials[1]Potential for unwanted differentiation (e.g., fibrosis, tumorigenicity)[1]Immunogenicity and variability of MSC preparationsPossible impairment of mature cell function (excessive signaling, e.g. SHh in β-cells)[2]
06

Interacting drugs

Cyclopamine (Hedgehog pathway inhibitor)[2]

3 more in the full profile.

07

Biomarkers

CD73, CD90, CD105 (MSC surface markers)SHh, IHh (Hedgehog pathway components)[2]Ascl2 (intestinal stem cell regeneration)[1]

Beyond the preview

Go deeper on Mesenchymal stromal cell (MSC) (MSC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesenchymal stromal cell (MSC) (MSC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call